Saturday 17 October 2026 Export ARWR’s income statement to Excel — free account

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024. In the quarter to June 2026, revenue grew 171.0%, EPS fell 7.94%, free cash flow fell 15.4% and total debt rose 259.5%, each against the same quarter a year earlier.

55.90 2.60 −4.44%

Follow ARWR

Alert me

Market cap: $8.3B
P/E: 0.0×
Fwd P/E: −23.1×
Dividend yield: —
F-score: 5/9
Altman Z: 2.98
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 37.34

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	9	3	—	1	2	1	—	—	2	—	—

Insider Ownership 7.26%

Capital & Financial Ratios $m

Market Cap 8,260.00

Revenue 669.50

Net Income (272.13)

Free Cash Flow (75.11)

Net Debt (737.89)

Current Ratio 5.90

Debt/Equity 1.85

P/E ratio 0.00

Fwd P/E (23.10)

P/S ratio 11.97

P/B ratio 17.20

Past 5Y EPS Growth —

This Y EPS Growth (35,135.10%)

Next Y EPS Growth (37.82%)

Next Y revenue growth (44.34%)

Next 5Y EPS Growth 11.96%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.20%

10-year low 10-year high

P/B against its own 10 years 85.33%

10-year low 10-year high

EV/Sales against its own 10 years 22.38%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	404	681	919	1,602
Receivables	—	—	7	9
Inventory	—	—	—	—
Other	4	5	14	36
	416	695	951	1,671

	2023	2024	2025	Q'26
Payables	36	11	18	28
ST’ Debt	11	—	40	40
Other	0	0	11	6
	105	103	195	283

Compound Annual Growth %

	10y	5y	3y
Sales	115.61%	56.63%	50.52%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	16.47%	1.74%	6.37%

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	264	74	75	—	—
’25	3	543	28	256	829
’24	4	—	—	—	4
’23	63	146	16	16	241
’22	27	152	32	32	243
’21	21	33	46	38	138
’20	29	24	27	8	88

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	13	84	(177)	—	—
’25	(146)	460	(155)	20	180
’24	(118)	(92)	(115)	(137)	(463)
’23	(76)	(32)	(21)	(26)	(154)
’22	(61)	63	(69)	(69)	(136)
’21	(39)	264	(30)	(24)	171
’20	(24)	(28)	(33)	(11)	(96)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	11	82	(181)	—	—
’25	(154)	455	(157)	13	157
’24	(186)	(126)	(130)	(162)	(604)
’23	(114)	(59)	(67)	(90)	(331)
’22	(67)	58	(78)	(101)	(189)
’21	(43)	257	(34)	(32)	148
’20	(28)	(31)	(36)	(13)	(108)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	0.22	(0.93)	(1.36)	—	—
’25	(1.39)	2.75	(1.26)	(0.18)	(0.01)
’24	(1.24)	(1.02)	(1.38)	(1.38)	(5.00)
’23	(0.39)	0.45	(0.96)	(1.03)	(1.92)
’22	(0.60)	0.41	(0.68)	(0.81)	(1.67)
’21	(0.20)	(0.26)	(0.29)	(0.61)	(1.36)
’20	(0.03)	(0.20)	(0.13)	(0.48)	(0.84)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.20	1.42	3.57	11.67	19.51	57.92	26.81	20.67	17.05	9.57	Analyst estimates 2026–2028 Powerpack
	High	8.22	4.54	22.39	73.72	86.75	93.66	70.09	42.48	39.83	72.36
People
People	Employees	94	93	95	109	232	329	397	525	609	711
	Revenue/emp, $m	0.00	0.34	0.17	1.55	0.38	0.42	0.61	0.46	0.01	1.17
Income, $m
Income, $m	Revenue	0	31	16	169	88	138	243	241	4	829
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(82)	(34)	(54)	68	(85)	(141)	(173)	(206)	(612)	52
	EBT margin, %	(51,623.88)	(109.46)	(337.30)	40.37	(96.09)	(101.85)	(71.01)	(85.78)	(17,247.54)	6.21
	Net income	(82)	(34)	(54)	68	(85)	(141)	(176)	(209)	(610)	30
	Depreciation	3	5	5	6	6	9	13	10	15	18
Per share, $
Per share, $	Revenue	0.00	0.43	0.19	1.80	0.87	1.33	2.31	2.26	0.03	6.20
	Earnings	(1.34)	(0.47)	(0.65)	0.69	(0.84)	(1.36)	(1.67)	(1.92)	(5.00)	(0.01)
	Cash flow	(1.06)	(0.32)	(0.56)	1.84	(0.95)	1.65	(1.29)	(1.44)	(3.86)	1.34
	Capex	(0.06)	(0.11)	(0.02)	(0.13)	(0.12)	(0.23)	(0.50)	(1.66)	(1.18)	(0.17)
	Free cash flow	(1.12)	(0.43)	(0.58)	1.72	(1.07)	1.42	(1.79)	(3.10)	(5.05)	1.17
	Book value	1.56	1.09	1.14	2.60	4.58	3.94	3.97	2.69	1.60	3.76
	Shares, m	61	74	84	94	101	104	105	107	120	134
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	40.84	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2,831.07	10.47	99.53	15.67	49.29	46.84	14.33	11.64	12.77	5.56
	P/B	4.72	4.07	16.87	10.84	9.39	15.84	8.33	9.76	12.14	9.16
	EV/Sales	2,308.47	8.46	94.92	14.15	45.94	44.36	13.11	11.56	11.24	4.76
	EV/FCF	(5.36)	(8.34)	(31.50)	14.83	(37.52)	41.52	(16.88)	(8.41)	(3.38)	25.17
Cash, $m
Cash, $m	Operating cash flow	(64)	(24)	(47)	173	(96)	171	(136)	(154)	(463)	180
	Capex	(4)	(8)	(1)	(12)	(12)	(24)	(53)	(177)	(141)	(23)
	Free cash flow	(68)	(32)	(49)	161	(108)	148	(189)	(331)	(604)	157
Balance, $m
Balance, $m	Working capital	65	49	66	168	282	238	266	311	592	755
	Total debt	3	3	2	—	21	26	82	383	393	255
	Net debt	(83)	(63)	(74)	(259)	(294)	(342)	(295)	(20)	(288)	(664)
	Shareholders’ equity	95	81	95	244	462	409	418	287	191	503
Returns, %
Returns, %	ROA	(62.76)	(29.61)	(50.50)	29.46	(19.39)	(22.85)	(25.11)	(28.17)	(62.93)	(0.13)
	ROIC	(412.49)	(129.96)	(166.22)	0.00	(34.78)	(139.91)	(90.32)	(47.98)	0.00	0.00
	ROE	(79.87)	(39.09)	(61.84)	40.07	(23.96)	(32.36)	(42.57)	(58.19)	(250.72)	(0.47)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
CAI Caris Life Sciences,�Inc.	$9.0B	81.3×	163×	+45.38% (above 0%: growing)	n/m	+8.47% (above 0%: growing)	68.10%	10.21%	Compare
CYTK Cytokinetics, Incorporated	$8.9B	— (loss-making)	— (loss-making)	−57.13% (below 0%: shrinking)	n/m	−24.02% (below 0%: shrinking)	80.46%	(625.95%)	Compare
PTGX Protagonist Therapeutics, Inc.	$8.8B	106×	25.0×	+3,749.17% (above 0%: growing)	n/m	+839.65% (above 0%: growing)	100.00%	74.37%	Compare
TGTX TG Therapeutics, Inc.	$8.6B	17.8×	29.4×	+70.27% (above 0%: growing)	−73.68% (below 0%: shrinking)	+427.05% (above 0%: growing)	82.86%	9.02%	Compare
AXSM Axsome Therapeutics, Inc.	$8.5B	— (loss-making)	— (loss-making)	+45.54% (above 0%: growing)	n/m	−2.98% (below 0%: shrinking)	93.79%	(22.73%)	Compare
ARWR Arrowhead Pharmaceuticals, Inc.	$8.3B	— (loss-making)	— (loss-making)	+171.02% (above 0%: growing)	n/m	−15.43% (below 0%: shrinking)	100.00%	(226.03%)
ABVX Abivax SA Sponsored ADR	$8.1B	— (loss-making)	—	—	n/m	−48.28% (below 0%: shrinking)	0.00%	0.00%	Compare
SYRE Spyre Therapeutics, Inc.	$7.4B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−50.07% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$8.7B	81.3×	29.4×	+45.54%	—	+2.75%	81.66%	0.00%

All 614 Biotechnology stocks →

Arrowhead Pharmaceuticals, Inc. (ARWR) key facts

Strength: Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ARWR traded at $55.90, a market capitalization of $8.3 billion.
Return on equity was −0.47% and debt-to-equity 1.85.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.98 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.